Caris Life Sciences, Inc.
NASDAQCaris Life Sciences heads into Thursday's earnings print with one strikingly unusual signal: options traders have turned their most bullish in months, even as the stock has been in freefall. The clearest anomaly is the options setup. The put/call ratio has collapsed to 0.79 — more than three standard deviations below its 20-day average of 1.37, and the lowest reading in the past…
Snapshot as of 20 May 2026
Caris Life Sciences heads into Thursday's earnings print with one strikingly unusual signal: options traders have turned their most bullish in months, even as the stock has been in freefall. The clearest anomaly is the…
Caris Life Sciences delivered a Q1 revenue beat and reaffirmed full-year guidance, then watched its stock collapse anyway — down 19% the day after results and 13% on the week to $16.15. The gap between the reported…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CAI — free to start on ORTEX.
Sign up for free →Open CAI on ORTEX